Clinical Trial Update: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC [Phase 2]

View source ↗

Summary

A randomized Phase 2 trial assessing cemiplimab with or without ISA101b in HPV16-positive oropharyngeal squamous cell carcinoma is underway, with the study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv16 Positive
• Squamous Cell Carcinoma of the Oropharynx

Drugs mentioned

• Cemiplimab (cemiplimab)
• ISA101b (ISA101b)

Snippet

Sponsor: ISA Pharmaceuticals | Conditions: Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive | Phase 2 | Status: UNKNOWN